Halda Therapeutics

Halda Therapeutics

生物技术研究

New Haven,Connecticut 5,177 位关注者

Taking Hold, Conquering Cancer. Discovering novel medicines to target cancer and overcome drug resistance.

关于我们

Halda is inventing novel precision medicines for oncology. Specifically, we are developing RIPTAC? therapeutics, a new drug modality for the treatment of cancer. Founded by world renowned Yale scientist, Professor Craig Crews, Halda invented RIPTAC therapeutics as an innovative cancer treatment approach that does not rely on traditional oncogenic disease drivers to target cancer. This powerful technology is designed to overcome the known bypass mechanisms of drug resistance, a common limitation of today’s precision cancer medicines. Using a novel ‘hold and kill’ mechanism, RIPTAC therapeutics target cancer cells selectively by bringing two proteins together in a tightly regulated manner, causing the loss of an essential function for cell survival and subsequent cancer cell death. We have built a pipeline of RIPTAC therapeutics for major cancer types, uniquely addressing the unmet needs of drug resistant cancer patients, and we will continue to invent new medicines using our proprietary platform technology. We are a bold company where collaboration, passion, and creativity thrive, all of which allows us to push the boundaries of drug discovery to identify better solutions. Halda is proud to be a New Haven, CT based biotech, located with headquarters and state-of-the-art labs in Science Park.

网站
https://haldatherapeutics.com/
所属行业
生物技术研究
规模
11-50 人
总部
New Haven,Connecticut
类型
私人持股

地点

  • 主要

    115 Munson Street

    Suite 101

    US,Connecticut,New Haven,06511

    获取路线

Halda Therapeutics员工

动态

相似主页

查看职位

融资

Halda Therapeutics 共 4 轮

上一轮

B 轮

US$126,000,000.00

Crunchbase 上查看更多信息